ORCID
- Hobart, Jeremy: 0000-0002-2114-7920
DOI
10.1007/s40263-018-0586-5
Publication Date
2019-01-01
Publication Title
CNS Drugs
Volume
33
Issue
1
ISSN
1172-7047
Embargo Period
2019-02-12
Organisational Unit
Peninsula Medical School
First Page
61
Last Page
79
Recommended Citation
Hobart, J., Ziemssen, T., Feys, P., Linnebank, M., Goodman, A., Farrell, R., Hupperts, R., Blight, A., Englishby, V., McNeill, M., Chang, I., & Elkins, J. (2019) 'Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine', CNS Drugs, 33(1), pp. 61-79. Available at: https://doi.org/10.1007/s40263-018-0586-5
